Introduction
============

Diabetes management requires coordinated efforts to change the patient's lifestyle to include a heathy diet and regular exercise, and to manage multiple risk factors, to prevent or delay complications such as stroke \[[@b1-jos-2019-00038]-[@b3-jos-2019-00038]\]. Patients with hyperglycemia or diabetes mellitus (DM) are at high risk of cerebrovascular ischemic stroke \[[@b4-jos-2019-00038],[@b5-jos-2019-00038]\]. DM is also associated with poor outcome in patients with cerebral hemorrhage \[[@b6-jos-2019-00038]\]. However, it is unclear whether it is better to prescribe intensive glucose-lowering treatment than conventional treatment for stroke management, and whether specific antidiabetic agents are safer and more efficacious than other drugs for stroke management.

Here, we discuss the mechanisms underlying the relationship between glucose homeostasis and stroke development, and provide an overview of the efficacy of glucose-lowering treatment in stroke management. We also discuss evidence from recent large clinical trials of thiazolidinedione (TZD) and new antidiabetic medications such as dipeptidyl peptidase-4 (DPP4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagonlike peptide-1 (GLP1) analogues, which suggest the potential of these agents in primary and secondary stroke prevention.

Glucose metabolism and stroke
=============================

The association between DM and stroke involves the interplay of complex mechanisms, including various hemodynamic and metabolic pathways ([Figure 1](#f1-jos-2019-00038){ref-type="fig"}). DM is characterized by chronic low-grade inflammation, oxidative stress, endothelial dysfunction, hypercoagulability, dyslipidemia, and insulin resistance \[[@b7-jos-2019-00038]\]. These factors contribute individually and collectively to diabetic macrovascular complications. Three distinct pathways are involved in diabetes-associated increased vasculopathy: increased production of advanced glycosylation end products (AGEs) \[[@b8-jos-2019-00038]\], increased reactive oxygen species (ROS) production and oxidative damage to vessels \[[@b9-jos-2019-00038]\], and activation of the aldose reductase pathway, which is driven by high blood glucose concentration \[[@b10-jos-2019-00038]\]. Activation of protein kinase C (PKC) isozymes is also involved in diabetes-related vascular complications \[[@b10-jos-2019-00038]\].

High circulatory glucose concentrations facilitate the nonenzymatic glycosylation of proteins in the blood vessel walls, resulting in AGE formation. Binding of AGE to its receptors aggravates atherogenicity by accelerating oxidation and uptake of low density lipoprotein (LDL) \[[@b8-jos-2019-00038]\]. Hyperglycemia stimulates the upregulation of AGEs. Moreover, nuclear factor κB and activator protein-1 increase proatherogenic gene expression and recruit numerous mediators of atherogenesis, including white blood cells, adhesion molecules, monocyte chemoattractant protein-1, and other inflammatory cytokines \[[@b11-jos-2019-00038]\].

Hyperglycemia-induced ROS generation and insulin resistance damage vascular smooth muscle and endothelial cells \[[@b12-jos-2019-00038]\]. Superoxide anions neutralize nitric oxide (NO) by forming peroxynitrite ions, which decrease the bioavailability of endothelium-derived NO \[[@b13-jos-2019-00038]\]. This inhibits endothelium-mediated vasodilation, stimulates abnormal platelet activation, and increases vascular smooth muscle cell proliferation and migration ([Figure 1](#f1-jos-2019-00038){ref-type="fig"}). ROS also increases LDL oxidation in vessel walls \[[@b13-jos-2019-00038]\].

Evidence suggests the role of PKC activation in hyperglycemiainduced vascular and endothelial dysfunction \[[@b10-jos-2019-00038]\]. Glucose transported into vascular cells stimulates *de novo* synthesis of diacylglycerol and PKC activation. PKC isoforms activation stimulates proatherosclerotic gene expression and vascular cell proliferation and migration, and impairs NO-mediated vasodilation. PKC activation also increases vascular endothelial cell permeability \[[@b14-jos-2019-00038]\].

The relationship between direct clinical risk factors and their roles in stroke development is illustrated in [Figure 2](#f2-jos-2019-00038){ref-type="fig"}. In addition to hyperglycemia and insulin resistance, high blood pressure, dyslipidemia, and smoking are implicated in the pathogenesis of stroke by increasing peripheral resistance and accelerating atherosclerosis. High urinary albumin excretion is another independent predictor of stroke in diabetes patients \[[@b15-jos-2019-00038]\]. These factors aggravate inflammation and increase oxidative stress, leading to endothelial dysfunction, increased thrombotic activity, and accelerated vascular smooth muscle cell proliferation and migration. These processes contribute to thrombus formation and plaque progression, which increase stroke risk.

Diabetic autonomic neuropathy and retinopathy are also risk factors for stroke \[[@b16-jos-2019-00038],[@b17-jos-2019-00038]\]. Therefore, several clinical factors are involved in increasing stroke risk.

Ideal approach to decreasing the risk of cardiovascular outcomes in diabetes patients
=====================================================================================

Evidence for the beneficial effects of intensive glycemic control in preventing cardiovascular diseases is inconclusive. However, intensive glycemic control as a part of a multifactorial intervention for atherosclerotic risk factors was effective in reducing cardiovascular disease risk and overall mortality in the Steno-2 study \[[@b1-jos-2019-00038],[@b18-jos-2019-00038]\] and cerebrovascular disease risk in the Japan Diabetes Outcome Intervention Trial 3 (J-DOIT3) study \[[@b19-jos-2019-00038]\]. The Steno-2 trial was the first to investigate the impact of multifactorial interventions in patients with type 2 diabetes (T2D), even though the sample size was small (n=160). Investigators treated study participants with multiple pharmacological agents and implemented lifestyle modifications that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria. This multifactorial intervention with intensive glycemic control (target glycosylated hemoglobin \[HbA1c\] level \<6.5%) reduced the incidence of the composite cardiovascular endpoint (hazard ratio \[HR\], 0.47; 95% confidence interval \[CI\], 0.24 to 0.73; *P*=0.008) \[[@b18-jos-2019-00038]\] and overall mortality (HR, 0.54; 95% CI, 0.32 to 0.89; *P*=0.02) \[[@b1-jos-2019-00038]\]. Another study involving Japanese patients with diabetes (the J-DOIT3 study) included an intensified intervention with tight glycemic control (target HbA1c \<6.2%). This study observed substantial benefit for cerebrovascular event prevention, including stroke and the need for carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting, compared with that associated with conventional therapy (target HbA1c \<6.9%) in patients with T2D (HR, 0.42; 95% CI, 0.24 to 0.74; *P*=0.002) \[[@b19-jos-2019-00038]\]. The success of multifactorial intervention trials in reducing atherosclerotic vascular disease risk suggests the complex multifactorial nature of atherosclerosis. Therefore, focusing on a single risk factor may not be sufficient to alter its progression.

Mechanistically, severe hypoglycemia may aggravate brain injury \[[@b20-jos-2019-00038]\] because the brain uses glucose as its primary fuel. Intensive glucose lowering with antidiabetic medications that do not induce hypoglycemia is helpful in stroke prevention. In addition, hyperglycemia increases stroke risk even in prediabetes patients \[[@b21-jos-2019-00038]\]. Therefore, controlling hyperglycemia to achieve normal glucose levels may be beneficial to prevent cerebrovascular disease.

TZD and new antidiabetic agents such as DPP4 inhibitors, SGLT2 inhibitors, and GLP1 analogues do not induce hypoglycemia. This may be why an active glucose-lowering approach with these agents was shown to be neutral (DPP4 inhibitors) or beneficial (TZD, SGLT2 inhibitors, and several GLP1 analogues) on cardiovascular outcomes compared with the effects of previous agents such as sulfonylurea and insulin. Optimal glucose control that does not induce hypoglycemia may therefore be the ideal approach to achieve better cerebrovascular outcomes.

Randomized controlled trials with TZD and new agents
====================================================

The results of stroke in randomized controlled trials (RCTs) with TZD and new antidiabetic agents are summarized in [Table 1](#t1-jos-2019-00038){ref-type="table"}.

TZDs
----

The beneficial effects of TZDs have been shown in clinical studies through carotid ultrasonography to measure carotid intimamedia thickness (IMT), a surrogate marker of cerebrovascular diseases. Carotid IMT progression was significantly attenuated after treatment with rosiglitazone, a TZD, for 48 weeks compared with that after placebo treatment (--0.012 mm vs. 0.031 mm, respectively; *P*=0.03) in non-diabetes patients \[[@b22-jos-2019-00038]\]. In patients with T2D, carotid IMT decreased significantly more after pioglitazone treatment for 24 weeks (--0.054 mm) than after glimepiride treatment (--0.002 mm, *P*\<0.005) \[[@b23-jos-2019-00038]\]. These changes were accompanied by insulin resistance attenuation. TZDs may therefore act as insulin sensitizers and play a role in preventing or regressing atherosclerosis, particularly in the carotid artery.

The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study is a prospective, double-blind study of 5,238 patients with T2D with a history of macrovascular disease. In this study, pioglitazone did not reduce composite cardiovascular outcome risk, including death from any cause, nonfatal myocardial infarction, stroke, acute coronary syndrome, leg amputation, coronary revascularization, or leg revascularization (HR, 0.90; event rate: 19.7% \[514/2,605\] for pioglitazone vs. 21.7% \[572/2,633\] for placebo; 95% CI, 0.80 to 1.02) \[[@b24-jos-2019-00038]\]. The rates of stroke did not differ between the two groups (HR, 0.81; event rate: 3.3% \[86/2,605\] in the pioglitazone group vs. 4.1% \[107/2,633\] in the placebo group; 95% CI, 0.61 to 1.07) ([Figure 3](#f3-jos-2019-00038){ref-type="fig"}). In a later analysis of patients from the PROactive study with previous stroke, the rate of fatal or nonfatal stroke events was significantly lower in the pioglitazone group than that in the placebo group (HR, 0.53; event rate: 5.6% in the pioglitazone group vs. 10.2% in the placebo group; 95% CI, 0.34 to 0.85) \[[@b25-jos-2019-00038]\].

The Insulin Resistance Intervention after Stroke (IRIS) study evaluated the efficacy of pioglitazone in 3,876 non-diabetes patients who previously experienced ischemic stroke or transient ischemic attack (TIA) \[[@b26-jos-2019-00038]\]. Pioglitazone therapy reduced the occurrence of stroke and myocardial infarction (event rate: 9.0% in the pioglitazone group vs. 11.8% in the placebo group; HR, 0.76; 95% CI, 0.62 to 0.93) ([Figure 3](#f3-jos-2019-00038){ref-type="fig"}) \[[@b26-jos-2019-00038]\]. However, the rate of stroke alone did not differ between the pioglitazone and placebo groups (HR, 0.82; 95% CI, 0.61 to 1.10) ([Figure 3](#f3-jos-2019-00038){ref-type="fig"}).

In a review of RCTs that compared TZDs and placebo for the secondary prevention of stroke and related vascular events in people who had experienced stroke or TIA, TZD reduced stroke recurrence (relative risk, 0.52; 95% CI, 0.34 to 0.80) \[[@b27-jos-2019-00038]\]. Therefore, TZDs may reduce recurrent stroke and related vascular event risk both in patients with T2D and in those with insulin resistance.

DPP4 inhibitors
---------------

DPP4 inhibitors are new antidiabetic agents for T2D \[[@b28-jos-2019-00038]\] that do not induce hypoglycemia or weight gain. Although these and GLP1 analogues have similar incretin-based activities, their effects on cardiovascular disease risk differ \[[@b29-jos-2019-00038]\]. Cardiovascular safety trials of DPP4 inhibitors such as saxagliptin \[[@b30-jos-2019-00038]\], alogliptin \[[@b31-jos-2019-00038]\], sitagliptin \[[@b32-jos-2019-00038]\], and linagliptin \[[@b33-jos-2019-00038]\] showed neutral effects on the composite outcome of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. Besides these safety trials \[[@b30-jos-2019-00038]-[@b32-jos-2019-00038]\], no study has focused on the effects of DPP4 inhibitors on the primary or secondary prevention of stroke alone. HRs for the outcome of ischemic stroke, nonfatal stroke, and fatal or nonfatal stroke were 1.11 (95% CI, 0.88 to 1.39; *P*=0.38), 0.91 (95% CI, 0.55 to 1.50; *P*=0.71), 0.97 (95% CI, 0.79 to 1.19; *P*=0.76), and 1.02 (95% CI, 0.89 to 1.17; *P*=0.74) for saxagliptin, alogliptin, sitagliptin, and linagliptin, respectively ([Figure 3](#f3-jos-2019-00038){ref-type="fig"}).

SGLT2 inhibitors
----------------

SGLT2 inhibitors are emerging antidiabetic agents \[[@b34-jos-2019-00038]\] that show cardiovascular benefits. Empagliflozin resulted in a beneficial cardiovascular outcome in the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial \[[@b35-jos-2019-00038]\]. The primary composite outcome, including death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurred in 10.5% of patients in the empagliflozin group and 12.1% of those in the placebo group (HR, 0.86; 95.02% CI, 0.74 to 0.99). Cardiovascular risk was reduced as early as 6 months, suggesting the cardiovascular benefit associated with empagliflozin is unlikely to be induced by its glucose-lowering properties. Furthermore, empagliflozin therapy was associated with an increased but nonsignificant risk of ischemic stroke (HR, 1.24; 95% CI, 0.92 to 1.67; *P*=0.16).

The CANagliflozin CardioVascular Assessment Study (CANVAS) program showed that patients treated with canagliflozin had a lower risk of cardiovascular events than those who received the placebo. However, canagliflozin showed no benefit in preventing stroke, although the point estimate was \<1 for fatal or nonfatal stroke compared with the placebo (HR, 0.87; 95% CI, 0.69 to 1.09) \[[@b36-jos-2019-00038]\].

In the Dapagliflozin Effect on CardiovascuLAR Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI58) study, 40.6% of participants showed established atherosclerotic cardiovascular disease and 59.4% had multiple cardiovascular risk factors. Dapagliflozin therapy was not superior in terms of the original primary cardiovascular outcome (HR, 0.93; 95% CI, 0.84 to 1.03) but showed benefits in reducing the risk of cardiovascular mortality or hospitalization for heart failure (HR, 0.83; 95% CI, 0.73 to 0.95) \[[@b37-jos-2019-00038]\]. The point estimates for ischemic stroke were similar in the dapagliflozin and placebo arms (HR, 1.01; 95% CI, 0.84 to 1.21) ([Figure 3](#f3-jos-2019-00038){ref-type="fig"}).

A recent population-based observational study showed that SGLT2 inhibitors (dapagliflozin, empagliflozin, or canagliflozin) were associated with reduced cardiovascular mortality compared to other glucose-lowering drugs (HR, 0.53; 95% CI, 0.40 to 0.71; *P*\<0.05) \[[@b38-jos-2019-00038]\]. Furthermore, no difference in nonfatal stroke risk was observed between the groups treated with the SGLT2 inhibitor and placebo (HR, 0.86; 95% CI, 0.72 to 1.04). A meta-analysis of SGLT2 inhibitors and stroke risk also showed the neutral effects of SGLT2 inhibitors on stroke risk compared to that of the placebo \[[@b39-jos-2019-00038]\]. Evidence therefore suggests that SGLT2 inhibitor use is associated with reduced rates of cardiovascular events and mortality. However, in cardiovascular outcome trials, SGLT2 inhibitors showed inconsistent or nonsignificant effects on stroke risk.

GLP1 analogues
--------------

Among five GLP1 analogues evaluated, liraglutide \[[@b40-jos-2019-00038]\], semaglutide \[[@b41-jos-2019-00038]\], and albiglutide \[[@b42-jos-2019-00038]\] showed superiority in terms of composite cardiovascular outcome. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) \[[@b40-jos-2019-00038]\] trial, the HR for fatal or nonfatal stroke was 0.86 (95% CI, 0.71 to 1.06; *P*=0.16) in the liraglutide-treated group. In the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide (SUSTAIN)-6 trial \[[@b41-jos-2019-00038]\], the HR for nonfatal stroke was 0.61 (95% CI, 0.38 to 0.99; *P*=0.04) in the semaglutide-treated group ([Figure 3](#f3-jos-2019-00038){ref-type="fig"}). The Harmony Outcomes study reported the superiority of albiglutide therapy in terms of the cardiovascular composite outcome (HR, 0.78; 95% CI, 0.68 to 0.90) but not of stroke (HR, 0.86; 95% CI, 0.66 to 1.14) \[[@b42-jos-2019-00038]\].

In contrast, lixisenatide treatment (Evaluation of Lixisenatide in Acute Coronary Syndrome \[ELIXA\] study) \[[@b43-jos-2019-00038]\] and once-weekly exenatide treatment (Exenatide Study of Cardiovascular Event Lowering \[EXSCEL\] study) \[[@b44-jos-2019-00038]\] were not superior in terms of stroke prevention or primary cardiovascular outcome. Therefore, studies of GLP1 analogues have produced inconsistent results for primary cardiovascular outcome, and their effects on stroke remain unclear.

Effects of individual antidiabetic agents on stroke
===================================================

TZDs
----

TZD is an agonist of peroxisome proliferator-activated receptor-γ (PPARγ), a nuclear receptor that regulates the transcription of genes involved in glucose and lipid metabolism. TZD increases insulin sensitivity in muscle and adipose tissue. However, PPARγ is expressed ubiquitously in other tissues and TZD exerts various pleiotropic effects. In terms of cerebrovascular diseases, TZD has both neuroprotective and antiatherosclerotic effects.

TZD improves the survival of neurons and glial cells, especially microglia, by reducing neuroinflammation \[[@b45-jos-2019-00038],[@b46-jos-2019-00038]\]. Accordingly, TZD is protective against both ischemic and excitotoxic neuronal stress \[[@b47-jos-2019-00038]\]. In mouse models of oxygen/glucose deprivation or glutamate/N-methyl-D-aspartate toxicity, PPARγ activation reduced neuronal death. However, mice lacking PPARγ in neurons were more susceptible to ischemic damage caused by focal cerebral ischemia \[[@b48-jos-2019-00038]\].

TZD also prevents atherosclerosis progression. *In vivo* studies of atherosclerosis have shown the antiatherosclerotic effects of TZDs. Rosiglitazone reduced atherosclerosis development in LDL-receptor-deficient mice \[[@b49-jos-2019-00038]\]. Lobeglitazone, another TZD, reduced atheroma burden in a balloon-injury model using highfat and high-fructose diet-fed apolipoprotein E (apoE)-knockout mice \[[@b50-jos-2019-00038]\]. These antiatherosclerotic effects may be independent of TZD's metabolic effects. Rosiglitazone showed beneficial effects on atherosclerosis independent of its effects on glucose and lipid levels in insulin-insufficient streptozotocintreated apoE-knockout mice \[[@b51-jos-2019-00038]\]. TZD can act on monocytes, endothelial cells, and vascular smooth muscle cells, which are crucial in the pathogenesis of atherosclerosis. TZD reduces proinflammatory cytokine production in monocytes, reduces adhesion molecule and chemokine expression in endothelial cells, and suppresses vascular smooth muscle cell proliferation and migration \[[@b52-jos-2019-00038]\]. Collectively, these effects may contribute to TZD's antiatherosclerotic properties.

There are few human mechanistic studies available, but TZD has also been shown to improve endothelial function in humans. In an RCT of patients with impaired glucose tolerance, endothelial function measured by brachial artery flow-mediated dilation improved after treatment with pioglitazone at 30 mg/day for 12 weeks \[[@b53-jos-2019-00038]\].

DPP4 inhibitors
---------------

DPP4 inhibitors increase circulating active GLP1 levels twofold, and potential antiatherosclerotic effects of DPP4 inhibitors may occur through GLP1 action. In apoE-knockout mice fed a high-fat diet, sitagliptin treatment decreased atherosclerotic plaque burden \[[@b54-jos-2019-00038],[@b55-jos-2019-00038]\]. However, in human studies, results were inconsistent. In two RCTs, alogliptin and sitagliptin therapy both attenuated the progression of carotid IMT, as measured via carotid ultrasonography \[[@b56-jos-2019-00038],[@b57-jos-2019-00038]\]. Conversely, another RCT of sitagliptin showed no effects on carotid IMT \[[@b58-jos-2019-00038]\]. In animal studies, DPP4 inhibitors also showed direct antistroke effects. In highfat diet-fed obese diabetic mice, linagliptin reduced brain infarct volume after middle cerebral artery occlusion, whereas glimepiride did not reduce brain ischemic lesions despite the greater attenuation of hyperglycemia \[[@b59-jos-2019-00038]\].

Several basic cell studies support the antiatherosclerotic effects of DPP4 inhibitors. Direct treatment of human vascular endothelial cells with sitagliptin decreased tumor necrosis factor-α-induced upregulation of adhesion molecules \[[@b60-jos-2019-00038]\]. Another *in vitro* study showed that sitagliptin decreased the production of ROS and increased endothelial NO synthase expression in endothelial cells \[[@b61-jos-2019-00038]\]. Therefore, the antiatherosclerotic effects of DPP4 inhibitors may be explained by their anti-inflammatory and antioxidant properties \[[@b62-jos-2019-00038]\].

GLP1 is not the only substrate of DPP4. DPP4 inactivates various peptide hormones including glucose-dependent insulinotropic polypeptide, B-type natriuretic peptide, stromal cellderived factor-1α (SDF1α), and substance P \[[@b63-jos-2019-00038]\]. In a recent study of mice, linagliptin treatment increased active SDF1α levels in brain tissue, and blockade of the SDF1α--C-X-C chemokine receptor type 4 (CXCR4) pathway with a specific antagonist abolished the positive effects of linagliptin on functional outcomes after stroke \[[@b64-jos-2019-00038]\].

SGLT2 inhibitors
----------------

SGLT2 inhibitors reduce hyperglycemia by bypassing the action of insulin and inducing glycosuria, and by reducing body weight and blood pressure \[[@b65-jos-2019-00038]\]. This unique mode of action modulates both hyperinsulinemia and conventional cardiovascular risk factors, including visceral obesity and albuminuria \[[@b66-jos-2019-00038]\]. We recently showed that the atheromatous plaque area in the aortic arch was significantly smaller after empagliflozin treatment than after sulfonylurea treatment in atherosclerosis-prone mice \[[@b67-jos-2019-00038]\]. Another study showed that empagliflozin treatment mitigated coronary artery thickening and remodeling and vascular dysfunction in *db/db* mice \[[@b68-jos-2019-00038]\]. Interestingly, SGLT2 inhibitors induce hyperketonemia, which may provide a "thrifty substrate" and lead to cardioprotective effects \[[@b69-jos-2019-00038]\]. Increased ketone levels may also directly affect the risk of stroke. In rodent studies, β-hydroxybutyrate, a ketone body that is increased after SGLT2 inhibitor treatment, could reduce brain infarct size by activating neuroprotective macrophages, and shift glucose metabolism toward reducing oxidative stress \[[@b70-jos-2019-00038],[@b71-jos-2019-00038]\]. Therefore, the diverse metabolic and hemodynamic effects of SGLT2 inhibitors appear to protect the cardiovascular system \[[@b72-jos-2019-00038]\], although it is unclear whether this also applies to the cerebrovascular system.

However, in the EMPA-REG OUTCOME trial, empagliflozin treatment slightly increased stroke risk \[[@b35-jos-2019-00038]\]. Dehydration and/or increased hematocrit was a proposed mechanism for this finding. However, studies of two other SGLT2 inhibitors reported inconsistent results: decreased stroke risk was observed in the canagliflozin group in the CANVAS program \[[@b36-jos-2019-00038]\] and a neutral effect was observed in the dapagliflozin group in the DECLARETIMI58 study \[[@b37-jos-2019-00038]\]. So far, it is unclear whether this is a class effect or that of individual drugs. Therefore, mechanistic studies of SGLT inhibitors are warranted.

GLP1 analogues
--------------

The cardioprotective effects of GLP1 have been consistently reported in preclinical studies, including endothelial function modulation via macrophage inflammatory response inhibition \[[@b73-jos-2019-00038]\], increased endothelial NO production, reduced vascular adhesion molecule release \[[@b74-jos-2019-00038]\], and suppressed vascular cell migration \[[@b75-jos-2019-00038]\]. In an atherosclerotic mouse model, a 4-week infusion of GLP1(7--36) amide, an active form of GLP1, suppressed atherosclerosis development and macrophage infiltration in the aortic wall \[[@b76-jos-2019-00038]\]. This effect was blocked by co-infusion with exendin(9--39), a specific GLP1 receptor antagonist, suggesting that GLP1 analogues exert an antiatherosclerotic effect through the GLP1 canonical receptor.

The antiatherosclerotic or vasculoprotective effects of GLP1 and GLP1 analogues have also been observed in rodent stroke models \[[@b77-jos-2019-00038]-[@b79-jos-2019-00038]\]. After cerebral ischemia-reperfusion injury, intraperitoneal or intracerebroventricular administration of liraglutide, a GLP1 analogue, consistently reduced the cerebral infarct volume in rats \[[@b78-jos-2019-00038]\]. These neuroprotective effects are induced by increasing antioxidant effects, upregulating vascular endothelial growth factor production \[[@b78-jos-2019-00038]\], and reducing proinflammatory cyclooxygenase-2 and prostaglandin E2 concentrations \[[@b79-jos-2019-00038]\]. These findings suggest that GLP1 analogues play a favorable role in the cardiovascular system through glucoregulatory, antiatherosclerotic, anti-inflammatory, and blood pressure-lowering effects, and by improving endothelial function \[[@b80-jos-2019-00038]\].

Conclusions
===========

So far, evidence suggests that optimal glucose control without inducing hypoglycemia has beneficial effects in the treatment of cardiovascular diseases including stroke. Accordingly, international guidelines for diabetes management recommend achieving a glycemic target goal to prevent or delay both micro- and macrovascular complications \[[@b81-jos-2019-00038],[@b82-jos-2019-00038]\].

Several recent large-scale studies of new antidiabetic medications suggest that these agents have beneficial effects in preventing the development of composite cardiovascular outcome and/or related mortality. However, their effects on stroke remain unclear. Empagliflozin treatment in the EMPA-REG OUTCOME trial showed a nonsignificant increase in stroke incidence \[[@b35-jos-2019-00038]\], although this contrasted with the effects of canagliflozin in the CANVAS program (nonsignificant decrease) \[[@b36-jos-2019-00038]\] and dapagliflozin in the DECLARE-TIMI58 study (neutral) \[[@b37-jos-2019-00038]\].

Although the semaglutide trial showed significant beneficial effects on nonfatal stroke, the cardiovascular outcome trials were underpowered for the specific stroke endpoints. More studies using ertugliflozin (SGLT2 inhibitor) and dulaglutide (once-weekly GLP1 analogue) are currently ongoing in the hope of improving vascular outcomes and total mortality in patients with diabetes at high stroke risk \[[@b83-jos-2019-00038],[@b84-jos-2019-00038]\]. Until the results of these studies are released, multifactorial interventions targeting individual cerebrovascular risk factors are required to improve clinical outcomes in diabetes patients after a stroke or at high risk of stroke. More mechanistic studies focusing on the mechanisms underlying the effects of these agents on stroke risk are needed.
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###### 

Stroke events in recent cardiovascular outcome studies of antidiabetic medications

  Drug (study name)                                                                                 Stroke events                      HR (95% CI)
  ------------------------------------------------------------------------------------------------- ---------------------------------- -------------------
  TZD                                                                                                                                  
   Pioglitazone (PROactive) \[[@b24-jos-2019-00038]\]                                               Stroke                             0.81 (0.61--1.07)
   Pioglitazone (IRIS) \[[@b26-jos-2019-00038]\]^[\*](#tfn1-jos-2019-00038){ref-type="table-fn"}^   Stroke                             0.82 (0.61--1.10)
  DPP4 inhibitors                                                                                                                      
   Saxagliptin (SAVOR-TIMI) \[[@b30-jos-2019-00038]\]                                               Ischemic stroke                    1.11 (0.88--1.39)
   Alogliptin (EXAMINE) \[[@b31-jos-2019-00038]\]                                                   Nonfatal stroke                    0.91 (0.55--1.50)
   Sitagliptin (TECOS) \[[@b32-jos-2019-00038]\]                                                    Fatal or nonfatal stroke           0.97 (0.79--1.19)
   Linagliptin (CARMELINA) \[[@b33-jos-2019-00038]\]                                                Fatal or nonfatal stroke           0.91 (0.67--1.23)
  SGLT2 inhibitors                                                                                                                     
   Empagliflozin (EMPA-REG OUTCOME) \[[@b35-jos-2019-00038]\]                                       Fatal or nonfatal stroke           1.18 (0.89--1.56)
   Canagliflozin (CANVAS) \[[@b36-jos-2019-00038]\]                                                 Fatal or nonfatal stroke           0.87 (0.69--1.09)
   Dapagliflozin (DECLARE-TIMI58) \[[@b37-jos-2019-00038]\]                                         Ischemic stroke                    1.01 (0.84--1.21)
  GLP1 analogues                                                                                                                       
   Lixisenatide (ELIXA) \[[@b43-jos-2019-00038]\]                                                   Stroke                             1.12 (0.79--1.58)
   Once weekly exenatide (EXSCEL) \[[@b44-jos-2019-00038]\]                                         Fatal or nonfatal stroke           0.85 (0.70--1.03)
   Liraglutide (LEADER) \[[@b40-jos-2019-00038]\]                                                   Fatal or nonfatal stroke, or TIA   0.86 (0.71--1.06)
   Semaglutide (SUSTAIN-6) \[[@b41-jos-2019-00038]\]                                                Nonfatal stroke                    0.61 (0.38--0.99)
   Albiglutide (HARMONY Outcome) \[[@b42-jos-2019-00038]\]                                          Nonfatal stroke                    0.86 (0.66--1.14)

HR, hazard ratio; CI, confidence interval; TZD, thiazolidinedione; PROactive, PROspective pioglitAzone Clinical Trial In macroVascular Events; IRIS, Insulin Resistance Intervention after Stroke; DPP4, dipeptidyl peptidase-4; SAVOR-TIMI, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction; EXAMINE, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; TECOS, Trial Evaluating Cardiovascular Outcomes with Sitagliptin; CARMELINA, Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus; SGLT2, sodium-glucose cotransporter-2; EMPA-REG OUTCOME, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes; CANVAS, CANagliflozin CardioVascular Assessment Study; DECLARE-TIMI58, Dapagliflozin Effect on CardiovascuLAR Events-Thrombolysis in Myocardial Infarction 58; GLP1, glucagon-like peptide-1; ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; TIA, transient ischemic attack; SUSTAIN-6, Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide 6; HARMONY, albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease.

IRIS study recruited participants with insulin resistance, but without type 2 diabetes mellitus.
